Activity Provided By:

ACHL

Opportunities with Novel Therapies to Treat the Entire Spectrum of Schizophrenia Symptoms

Overview / Abstract:	Available antipsychotic therapies for schizophrenia are effective in treating positive symptoms of schizophrenia yet significant unmet needs remain, including therapies that (1) are more effective in reducing negative and cognitive symptoms of schizophrenia; 2) have improved tolerability and adherence rates; and (3) that are effective in treating refractory schizophrenia. Fortunately, the schizophrenia treatment landscape is poised to change dramatically, offering new opportunities for patients. Designed with your questions in mind, this digital FAQ index offers succinct and relevant information for clinicians on an array of questions including: • What are some of the emerging therapies for schizophrenia, and how do they differ from current treatment options? • Which emerging therapies address negative and/or cognitive symptoms? • What is the latest clinical trial evidence around novel therapies? • What are the clinical implications of the latest evidence? Start the activity to find out the answers to these questions and more!
Expiration	Sep 30, 2025
Discipline(s)	Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physical Therapy CE, Physician CME, Physician Assistant CME
Format	Online
Credits / Hours	1.00
Accreditation	ACCME
Presenters / Authors / Faculty	Christoph U. Correll, MD Professor of Psychiatry and Molecular Medicine The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Professor of Psychiatric Neuroscience, Institute of Behavioral Science Feinstein Institutes for Medical Research New York, USA Professor and Chair, Department of Child and Adolescent Psychiatry Charité University Medicine Berline, Germany
Sponsors / Supporters / Grant Providers	Provided by the Academy for Continued Healthcare Learning (ACHL). Supported by an educational grant from Bristol Myers Squibb.
Keywords / Search Terms	ACHL CME, CE, Continuing Medical Education, CME/CE, Online Learning, Christoph U. Correll, MD, Digital FAQ, schizophrenia, antipsychotic therapies, treatment, D2, dopamine receptors, positive symptoms, negative symptoms, cognitive symptoms, dopamine antagonist, serotonin, 5HT, 5HT2A receptors, first-generation antipsychotic, FGA, second-generation antipsychotic, SGA, atypical antipsychotic, acetylcholine, muscarinic receptor Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map